Your browser doesn't support javascript.
loading
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer; He, Yi; Turner, Christopher D; Yellin, Michael J; Keler, Tibor; Davis, Thomas A; Stupp, Roger; Sampson, John H.
Afiliación
  • Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch.
  • Butowski N; Department of Neurological Surgery, University of California, San Francisco, CA, USA.
  • Tran DD; Washington University, St Louis, MO, USA.
  • Recht LD; Stanford University Medical Center, Palo Alto, CA, USA.
  • Lim M; The Johns Hopkins Hospital, Baltimore, MD, USA.
  • Hirte H; Juravinski Cancer Centre, Hamilton, ON, Canada.
  • Ashby L; Barrow Neurological Institute, Phoenix, AZ, USA.
  • Mechtler L; DENT Neurologic Institute, Buffalo, NY, USA.
  • Goldlust SA; John Theurer Cancer Center, Hackensack, NJ, USA.
  • Iwamoto F; Columbia University Medical Center, New York, NY, USA.
  • Drappatz J; University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • O'Rourke DM; Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Wong M; Westmead Hospital, Westmead, NSW, Australia.
  • Hamilton MG; University of Calgary, Department of Clinical Neurosciences, Division of Neurosurgery, Foothills Hospital, Calgary, AB, Canada.
  • Finocchiaro G; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Perry J; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Wick W; The University of Heidelberg and German Cancer Research Center, Heidelberg, Germany.
  • Green J; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • He Y; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • Turner CD; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • Yellin MJ; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • Keler T; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • Davis TA; Celldex Therapeutics, Inc, Hampton, NJ, USA.
  • Stupp R; Department of Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Sampson JH; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Lancet Oncol ; 18(10): 1373-1385, 2017 10.
Article en En | MEDLINE | ID: mdl-28844499
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Receptores ErbB Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Glioblastoma / Receptores ErbB Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article